Table 3 Incidence of AEs
Treatment-related AEs, n (%) | Osimertinib group (n = 40) | Osimertinib + RT group (n = 21) | P |
|---|---|---|---|
Any grade | 13 (32.5) | 10 (47.6) | 0.762 |
Fatigue | 1 (2.5) | 0 (0) | Â |
Rash | 5 (12.5) | 1 (4.7) | Â |
Diarrhea | 3 (7.5) | 1 (4.7) | Â |
Myocardial damage | 2 (5.0) | 0 (0) | Â |
Pneumonitis | 3 (7.5) | 0 (0) | Â |
Oral ulcer | 0 (0) | 1 (4.7) |  |
Leukoencephalopathy | 0 (0) | 6 (28.5) | Â |
Neutrophil count decreased | 6 (15.0) | 3 (14.2) | Â |
Grade ≥ 3 | 3 (7.5) | 4 (19.0) | 0.220 |
Neutrophil count decreased | 3 (7.5) | 1 (4.7) | Â |
Leukoencephalopathy | 0 | 3 (14.2) | Â |